nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—CYP2C8—Mometasone—systemic scleroderma	0.146	0.266	CbGbCtD
Lapatinib—ABCB1—Lisinopril—systemic scleroderma	0.0669	0.122	CbGbCtD
Lapatinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0606	0.11	CbGbCtD
Lapatinib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0583	0.106	CbGbCtD
Lapatinib—ABCB1—Captopril—systemic scleroderma	0.0501	0.091	CbGbCtD
Lapatinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0394	0.0716	CbGbCtD
Lapatinib—CYP2C19—Prednisone—systemic scleroderma	0.0391	0.071	CbGbCtD
Lapatinib—ABCB1—Prednisone—systemic scleroderma	0.0315	0.0573	CbGbCtD
Lapatinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0236	0.0429	CbGbCtD
Lapatinib—CYP3A4—Prednisone—systemic scleroderma	0.0189	0.0343	CbGbCtD
Lapatinib—ABCB1—Methotrexate—systemic scleroderma	0.0158	0.0287	CbGbCtD
Lapatinib—PIK3C2B—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00553	0.6	CbGdCrCtD
Lapatinib—ERBB2—connective tissue—systemic scleroderma	0.00413	0.0797	CbGeAlD
Lapatinib—TAP1—tendon—systemic scleroderma	0.00388	0.075	CbGeAlD
Lapatinib—ERBB2—smooth muscle tissue—systemic scleroderma	0.00377	0.0729	CbGeAlD
Lapatinib—ERBB2—skin of body—systemic scleroderma	0.00373	0.072	CbGeAlD
Lapatinib—PIK3C2B—tendon—systemic scleroderma	0.00365	0.0704	CbGeAlD
Lapatinib—PI4KB—smooth muscle tissue—systemic scleroderma	0.00354	0.0683	CbGeAlD
Lapatinib—TAP1—lung—systemic scleroderma	0.00341	0.0658	CbGeAlD
Lapatinib—PIK3C2B—lung—systemic scleroderma	0.0032	0.0618	CbGeAlD
Lapatinib—ERBB2—digestive system—systemic scleroderma	0.00298	0.0576	CbGeAlD
Lapatinib—ERBB4—tendon—systemic scleroderma	0.00284	0.0548	CbGeAlD
Lapatinib—PI4KB—tendon—systemic scleroderma	0.00266	0.0513	CbGeAlD
Lapatinib—ERBB2—lung—systemic scleroderma	0.00249	0.0481	CbGeAlD
Lapatinib—ERBB4—lung—systemic scleroderma	0.00249	0.0481	CbGeAlD
Lapatinib—PI4KB—lung—systemic scleroderma	0.00233	0.045	CbGeAlD
Lapatinib—EGFR—lung—systemic scleroderma	0.00211	0.0408	CbGeAlD
Lapatinib—ABCB1—blood vessel—systemic scleroderma	0.00105	0.0202	CbGeAlD
Lapatinib—CYP2C19—digestive system—systemic scleroderma	0.000928	0.0179	CbGeAlD
Lapatinib—ERBB2—Signaling by EGFR—CSK—systemic scleroderma	0.000821	0.00608	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000814	0.00603	CbGpPWpGaD
Lapatinib—ERBB2—Focal Adhesion—COL1A2—systemic scleroderma	0.00081	0.006	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR—CSK—systemic scleroderma	0.000809	0.00599	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000801	0.00594	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000799	0.00592	CbGpPWpGaD
Lapatinib—PIK3C2B—Exemestane—Prednisone—systemic scleroderma	0.000779	0.0846	CbGdCrCtD
Lapatinib—ERBB2—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.000774	0.00573	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—CD247—systemic scleroderma	0.000773	0.00573	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—GDF15—systemic scleroderma	0.000769	0.0057	CbGpPWpGaD
Lapatinib—EGFR—Androgen receptor signaling pathway—RHOB—systemic scleroderma	0.000762	0.00565	CbGpPWpGaD
Lapatinib—EGFR—Bladder Cancer—MMP1—systemic scleroderma	0.00076	0.00563	CbGpPWpGaD
Lapatinib—PIK3C2B—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000746	0.00553	CbGpPWpGaD
Lapatinib—ERBB2—Focal Adhesion—ITGAM—systemic scleroderma	0.000736	0.00545	CbGpPWpGaD
Lapatinib—CYP3A5—digestive system—systemic scleroderma	0.000731	0.0141	CbGeAlD
Lapatinib—EGFR—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000731	0.00542	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—BLK—systemic scleroderma	0.000716	0.0053	CbGpPWpGaD
Lapatinib—ERBB2—Focal Adhesion—BLK—systemic scleroderma	0.000681	0.00505	CbGpPWpGaD
Lapatinib—PIK3C2B—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	0.000677	0.00502	CbGpPWpGaD
Lapatinib—EGFR—a6b1 and a6b4 Integrin signaling—IL1A—systemic scleroderma	0.000668	0.00495	CbGpPWpGaD
Lapatinib—ERBB2—B Cell Activation—BLK—systemic scleroderma	0.000667	0.00494	CbGpPWpGaD
Lapatinib—ERBB4—B Cell Activation—BLK—systemic scleroderma	0.000657	0.00487	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—SELP—systemic scleroderma	0.000651	0.00483	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000645	0.00478	CbGpPWpGaD
Lapatinib—ERBB2—Exemestane—Prednisone—systemic scleroderma	0.000642	0.0697	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Mometasone—systemic scleroderma	0.000642	0.0697	CbGdCrCtD
Lapatinib—PIK3C2B—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000627	0.00465	CbGpPWpGaD
Lapatinib—EGFR—GAB1 signalosome—CSK—systemic scleroderma	0.000622	0.00461	CbGpPWpGaD
Lapatinib—CYP3A5—lung—systemic scleroderma	0.000611	0.0118	CbGeAlD
Lapatinib—Cough—Leflunomide—systemic scleroderma	0.00061	0.00241	CcSEcCtD
Lapatinib—Alopecia—Lisinopril—systemic scleroderma	0.000609	0.0024	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Mometasone—systemic scleroderma	0.000609	0.0661	CbGdCrCtD
Lapatinib—Dyspepsia—Captopril—systemic scleroderma	0.000609	0.0024	CcSEcCtD
Lapatinib—EGFR—Spinal Cord Injury—RHOB—systemic scleroderma	0.000608	0.00451	CbGpPWpGaD
Lapatinib—Cardiac failure—Prednisone—systemic scleroderma	0.000607	0.00239	CcSEcCtD
Lapatinib—PI4KB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000606	0.00449	CbGpPWpGaD
Lapatinib—Mental disorder—Lisinopril—systemic scleroderma	0.000604	0.00238	CcSEcCtD
Lapatinib—Decreased appetite—Captopril—systemic scleroderma	0.000601	0.00237	CcSEcCtD
Lapatinib—Malnutrition—Lisinopril—systemic scleroderma	0.0006	0.00237	CcSEcCtD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.0006	0.00445	CbGpPWpGaD
Lapatinib—Infection—Azathioprine—systemic scleroderma	0.0006	0.00237	CcSEcCtD
Lapatinib—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000597	0.00235	CcSEcCtD
Lapatinib—Fatigue—Captopril—systemic scleroderma	0.000596	0.00235	CcSEcCtD
Lapatinib—Myalgia—Leflunomide—systemic scleroderma	0.000595	0.00235	CcSEcCtD
Lapatinib—Arthralgia—Leflunomide—systemic scleroderma	0.000595	0.00235	CcSEcCtD
Lapatinib—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000594	0.00234	CcSEcCtD
Lapatinib—Constipation—Captopril—systemic scleroderma	0.000592	0.00233	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000591	0.00233	CcSEcCtD
Lapatinib—Palpitations—Mycophenolic acid—systemic scleroderma	0.000589	0.00232	CcSEcCtD
Lapatinib—Skin disorder—Azathioprine—systemic scleroderma	0.000586	0.00231	CcSEcCtD
Lapatinib—TAP1—Adaptive Immune System—CTLA4—systemic scleroderma	0.000586	0.00434	CbGpPWpGaD
Lapatinib—Cough—Mycophenolic acid—systemic scleroderma	0.000582	0.00229	CcSEcCtD
Lapatinib—Back pain—Lisinopril—systemic scleroderma	0.000581	0.00229	CcSEcCtD
Lapatinib—Vomiting—Pentoxifylline—systemic scleroderma	0.00058	0.00229	CcSEcCtD
Lapatinib—Rash—Pentoxifylline—systemic scleroderma	0.000576	0.00227	CcSEcCtD
Lapatinib—Dermatitis—Pentoxifylline—systemic scleroderma	0.000575	0.00227	CcSEcCtD
Lapatinib—Headache—Pentoxifylline—systemic scleroderma	0.000572	0.00226	CcSEcCtD
Lapatinib—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00057	0.00225	CcSEcCtD
Lapatinib—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000567	0.00224	CcSEcCtD
Lapatinib—Myalgia—Mycophenolic acid—systemic scleroderma	0.000567	0.00224	CcSEcCtD
Lapatinib—Infection—Leflunomide—systemic scleroderma	0.000566	0.00223	CcSEcCtD
Lapatinib—Gastrointestinal pain—Captopril—systemic scleroderma	0.000566	0.00223	CcSEcCtD
Lapatinib—Asthenia—Mometasone—systemic scleroderma	0.000565	0.00223	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000563	0.00222	CcSEcCtD
Lapatinib—ERBB2—Leptin signaling pathway—NOS3—systemic scleroderma	0.000562	0.00417	CbGpPWpGaD
Lapatinib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000561	0.00221	CcSEcCtD
Lapatinib—ERBB2—Axon guidance—RHOB—systemic scleroderma	0.000561	0.00415	CbGpPWpGaD
Lapatinib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000559	0.00221	CcSEcCtD
Lapatinib—Pruritus—Mometasone—systemic scleroderma	0.000557	0.0022	CcSEcCtD
Lapatinib—Anaemia—Lisinopril—systemic scleroderma	0.000555	0.00219	CcSEcCtD
Lapatinib—Skin disorder—Leflunomide—systemic scleroderma	0.000554	0.00219	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00055	0.00217	CcSEcCtD
Lapatinib—CYP3A4—digestive system—systemic scleroderma	0.000549	0.0106	CbGeAlD
Lapatinib—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000548	0.00216	CcSEcCtD
Lapatinib—Abdominal pain—Captopril—systemic scleroderma	0.000547	0.00216	CcSEcCtD
Lapatinib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000544	0.00215	CcSEcCtD
Lapatinib—Anorexia—Leflunomide—systemic scleroderma	0.000543	0.00214	CcSEcCtD
Lapatinib—Dry skin—Prednisone—systemic scleroderma	0.000543	0.00214	CcSEcCtD
Lapatinib—Nausea—Pentoxifylline—systemic scleroderma	0.000542	0.00214	CcSEcCtD
Lapatinib—Infection—Mycophenolic acid—systemic scleroderma	0.00054	0.00213	CcSEcCtD
Lapatinib—Diarrhoea—Mometasone—systemic scleroderma	0.000539	0.00213	CcSEcCtD
Lapatinib—Leukopenia—Lisinopril—systemic scleroderma	0.000537	0.00212	CcSEcCtD
Lapatinib—Renal failure acute—Methotrexate—systemic scleroderma	0.000536	0.00211	CcSEcCtD
Lapatinib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000534	0.00211	CcSEcCtD
Lapatinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000533	0.0021	CcSEcCtD
Lapatinib—Palpitations—Lisinopril—systemic scleroderma	0.00053	0.00209	CcSEcCtD
Lapatinib—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000529	0.00209	CcSEcCtD
Lapatinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000528	0.00208	CcSEcCtD
Lapatinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000526	0.00208	CcSEcCtD
Lapatinib—Cough—Lisinopril—systemic scleroderma	0.000524	0.00207	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000522	0.00206	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000521	0.00206	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000519	0.00205	CcSEcCtD
Lapatinib—Anorexia—Mycophenolic acid—systemic scleroderma	0.000518	0.00205	CcSEcCtD
Lapatinib—Insomnia—Leflunomide—systemic scleroderma	0.000516	0.00203	CcSEcCtD
Lapatinib—Myalgia—Lisinopril—systemic scleroderma	0.000511	0.00202	CcSEcCtD
Lapatinib—Arthralgia—Lisinopril—systemic scleroderma	0.000511	0.00202	CcSEcCtD
Lapatinib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000509	0.00201	CcSEcCtD
Lapatinib—Dyspnoea—Leflunomide—systemic scleroderma	0.000508	0.00201	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000508	0.002	CcSEcCtD
Lapatinib—Dyspepsia—Leflunomide—systemic scleroderma	0.000502	0.00198	CcSEcCtD
Lapatinib—Vomiting—Mometasone—systemic scleroderma	0.000501	0.00198	CcSEcCtD
Lapatinib—TAP1—Immune System—CSK—systemic scleroderma	0.000499	0.0037	CbGpPWpGaD
Lapatinib—Rash—Mometasone—systemic scleroderma	0.000497	0.00196	CcSEcCtD
Lapatinib—Asthenia—Captopril—systemic scleroderma	0.000496	0.00196	CcSEcCtD
Lapatinib—Dermatitis—Mometasone—systemic scleroderma	0.000496	0.00196	CcSEcCtD
Lapatinib—Decreased appetite—Leflunomide—systemic scleroderma	0.000496	0.00196	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000496	0.00196	CcSEcCtD
Lapatinib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000494	0.00195	CcSEcCtD
Lapatinib—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000493	0.00366	CbGpPWpGaD
Lapatinib—Headache—Mometasone—systemic scleroderma	0.000493	0.00195	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000492	0.00194	CcSEcCtD
Lapatinib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000492	0.00194	CcSEcCtD
Lapatinib—Fatigue—Leflunomide—systemic scleroderma	0.000492	0.00194	CcSEcCtD
Lapatinib—TAP1—Immune System—IRF5—systemic scleroderma	0.000491	0.00364	CbGpPWpGaD
Lapatinib—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00049	0.00193	CcSEcCtD
Lapatinib—Pruritus—Captopril—systemic scleroderma	0.000489	0.00193	CcSEcCtD
Lapatinib—Constipation—Leflunomide—systemic scleroderma	0.000488	0.00192	CcSEcCtD
Lapatinib—Infection—Lisinopril—systemic scleroderma	0.000487	0.00192	CcSEcCtD
Lapatinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000486	0.00192	CcSEcCtD
Lapatinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000485	0.00191	CcSEcCtD
Lapatinib—TAP1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000483	0.00358	CbGpPWpGaD
Lapatinib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000479	0.00189	CcSEcCtD
Lapatinib—ERBB2—Leptin signaling pathway—IL1B—systemic scleroderma	0.000479	0.00355	CbGpPWpGaD
Lapatinib—Neutropenia—Prednisone—systemic scleroderma	0.000478	0.00189	CcSEcCtD
Lapatinib—Abdominal pain—Azathioprine—systemic scleroderma	0.000477	0.00188	CcSEcCtD
Lapatinib—Skin disorder—Lisinopril—systemic scleroderma	0.000476	0.00188	CcSEcCtD
Lapatinib—EGFR—Direct p53 effectors—IRF5—systemic scleroderma	0.000475	0.00352	CbGpPWpGaD
Lapatinib—Diarrhoea—Captopril—systemic scleroderma	0.000473	0.00187	CcSEcCtD
Lapatinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000473	0.00187	CcSEcCtD
Lapatinib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000471	0.00186	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00047	0.00185	CcSEcCtD
Lapatinib—TAP1—Immune System—IRF8—systemic scleroderma	0.000469	0.00348	CbGpPWpGaD
Lapatinib—TAP1—Immune System—ITGAM—systemic scleroderma	0.000469	0.00348	CbGpPWpGaD
Lapatinib—TAP1—Immune System—CD247—systemic scleroderma	0.000469	0.00348	CbGpPWpGaD
Lapatinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000469	0.00185	CcSEcCtD
Lapatinib—Nausea—Mometasone—systemic scleroderma	0.000468	0.00185	CcSEcCtD
Lapatinib—Anorexia—Lisinopril—systemic scleroderma	0.000467	0.00184	CcSEcCtD
Lapatinib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000466	0.00184	CcSEcCtD
Lapatinib—Constipation—Mycophenolic acid—systemic scleroderma	0.000465	0.00184	CcSEcCtD
Lapatinib—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000465	0.00183	CcSEcCtD
Lapatinib—EGFR—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.00046	0.00341	CbGpPWpGaD
Lapatinib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00181	CcSEcCtD
Lapatinib—TAP1—Adaptive Immune System—CD40LG—systemic scleroderma	0.000456	0.00338	CbGpPWpGaD
Lapatinib—Abdominal pain—Leflunomide—systemic scleroderma	0.000451	0.00178	CcSEcCtD
Lapatinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000448	0.00177	CcSEcCtD
Lapatinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000448	0.00177	CcSEcCtD
Lapatinib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000447	0.00176	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000446	0.00176	CcSEcCtD
Lapatinib—Hypersensitivity—Azathioprine—systemic scleroderma	0.000445	0.00176	CcSEcCtD
Lapatinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000445	0.00175	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000445	0.00175	CcSEcCtD
Lapatinib—Insomnia—Lisinopril—systemic scleroderma	0.000443	0.00175	CcSEcCtD
Lapatinib—Vomiting—Captopril—systemic scleroderma	0.00044	0.00174	CcSEcCtD
Lapatinib—TAP1—Immune System—TNFAIP3—systemic scleroderma	0.000439	0.00325	CbGpPWpGaD
Lapatinib—Dyspnoea—Lisinopril—systemic scleroderma	0.000437	0.00172	CcSEcCtD
Lapatinib—Rash—Captopril—systemic scleroderma	0.000436	0.00172	CcSEcCtD
Lapatinib—Dermatitis—Captopril—systemic scleroderma	0.000436	0.00172	CcSEcCtD
Lapatinib—TAP1—Immune System—BLK—systemic scleroderma	0.000434	0.00322	CbGpPWpGaD
Lapatinib—Headache—Captopril—systemic scleroderma	0.000433	0.00171	CcSEcCtD
Lapatinib—Dyspepsia—Lisinopril—systemic scleroderma	0.000431	0.0017	CcSEcCtD
Lapatinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00043	0.0017	CcSEcCtD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.00043	0.00318	CbGpPWpGaD
Lapatinib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000429	0.00169	CcSEcCtD
Lapatinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000426	0.00168	CcSEcCtD
Lapatinib—Decreased appetite—Lisinopril—systemic scleroderma	0.000426	0.00168	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000423	0.00167	CcSEcCtD
Lapatinib—Fatigue—Lisinopril—systemic scleroderma	0.000422	0.00167	CcSEcCtD
Lapatinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000421	0.00166	CcSEcCtD
Lapatinib—Hypersensitivity—Leflunomide—systemic scleroderma	0.00042	0.00166	CcSEcCtD
Lapatinib—Constipation—Lisinopril—systemic scleroderma	0.000419	0.00165	CcSEcCtD
Lapatinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000417	0.00165	CcSEcCtD
Lapatinib—EGFR—Focal Adhesion—RHOB—systemic scleroderma	0.000415	0.00308	CbGpPWpGaD
Lapatinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000413	0.00163	CcSEcCtD
Lapatinib—Nausea—Captopril—systemic scleroderma	0.000411	0.00162	CcSEcCtD
Lapatinib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000409	0.00161	CcSEcCtD
Lapatinib—Asthenia—Leflunomide—systemic scleroderma	0.000409	0.00161	CcSEcCtD
Lapatinib—Pruritus—Leflunomide—systemic scleroderma	0.000403	0.00159	CcSEcCtD
Lapatinib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000402	0.00159	CcSEcCtD
Lapatinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000401	0.00158	CcSEcCtD
Lapatinib—ERBB2—Developmental Biology—RHOB—systemic scleroderma	0.0004	0.00296	CbGpPWpGaD
Lapatinib—Neutropenia—Methotrexate—systemic scleroderma	0.0004	0.00158	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR—CSK—systemic scleroderma	0.000397	0.00294	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000393	0.00291	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—COL1A2—systemic scleroderma	0.000392	0.0029	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000391	0.00154	CcSEcCtD
Lapatinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.00039	0.00154	CcSEcCtD
Lapatinib—Diarrhoea—Leflunomide—systemic scleroderma	0.00039	0.00154	CcSEcCtD
Lapatinib—ABCB1—digestive system—systemic scleroderma	0.000388	0.0075	CbGeAlD
Lapatinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000388	0.00153	CcSEcCtD
Lapatinib—Abdominal pain—Lisinopril—systemic scleroderma	0.000387	0.00153	CcSEcCtD
Lapatinib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000385	0.00152	CcSEcCtD
Lapatinib—Vomiting—Azathioprine—systemic scleroderma	0.000384	0.00151	CcSEcCtD
Lapatinib—Pneumonia—Methotrexate—systemic scleroderma	0.000383	0.00151	CcSEcCtD
Lapatinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000383	0.00151	CcSEcCtD
Lapatinib—Infestation NOS—Methotrexate—systemic scleroderma	0.000381	0.0015	CcSEcCtD
Lapatinib—Infestation—Methotrexate—systemic scleroderma	0.000381	0.0015	CcSEcCtD
Lapatinib—Rash—Azathioprine—systemic scleroderma	0.000381	0.0015	CcSEcCtD
Lapatinib—Dermatitis—Azathioprine—systemic scleroderma	0.00038	0.0015	CcSEcCtD
Lapatinib—Headache—Azathioprine—systemic scleroderma	0.000378	0.00149	CcSEcCtD
Lapatinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000378	0.00149	CcSEcCtD
Lapatinib—EGFR—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.000374	0.00277	CbGpPWpGaD
Lapatinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000373	0.00147	CcSEcCtD
Lapatinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000372	0.00147	CcSEcCtD
Lapatinib—Stomatitis—Methotrexate—systemic scleroderma	0.000372	0.00147	CcSEcCtD
Lapatinib—Angiopathy—Prednisone—systemic scleroderma	0.000372	0.00147	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000371	0.00146	CcSEcCtD
Lapatinib—Immune system disorder—Prednisone—systemic scleroderma	0.00037	0.00146	CcSEcCtD
Lapatinib—PIK3C2B—Metabolism—HSPG2—systemic scleroderma	0.000369	0.00273	CbGpPWpGaD
Lapatinib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000367	0.00145	CcSEcCtD
Lapatinib—Vomiting—Leflunomide—systemic scleroderma	0.000362	0.00143	CcSEcCtD
Lapatinib—Alopecia—Prednisone—systemic scleroderma	0.000362	0.00143	CcSEcCtD
Lapatinib—Hypersensitivity—Lisinopril—systemic scleroderma	0.000361	0.00142	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000361	0.00142	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—systemic scleroderma	0.00036	0.00142	CcSEcCtD
Lapatinib—Rash—Leflunomide—systemic scleroderma	0.000359	0.00142	CcSEcCtD
Lapatinib—Dermatitis—Leflunomide—systemic scleroderma	0.000359	0.00142	CcSEcCtD
Lapatinib—Mental disorder—Prednisone—systemic scleroderma	0.000359	0.00142	CcSEcCtD
Lapatinib—Nausea—Azathioprine—systemic scleroderma	0.000359	0.00141	CcSEcCtD
Lapatinib—Headache—Leflunomide—systemic scleroderma	0.000357	0.00141	CcSEcCtD
Lapatinib—Malnutrition—Prednisone—systemic scleroderma	0.000356	0.00141	CcSEcCtD
Lapatinib—PI4KB—Metabolism—HSPG2—systemic scleroderma	0.000356	0.00264	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—ITGAM—systemic scleroderma	0.000356	0.00264	CbGpPWpGaD
Lapatinib—TAP1—Immune System—CTLA4—systemic scleroderma	0.000355	0.00263	CbGpPWpGaD
Lapatinib—Asthenia—Lisinopril—systemic scleroderma	0.000351	0.00139	CcSEcCtD
Lapatinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000351	0.00138	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Prednisone—systemic scleroderma	0.00035	0.038	CbGdCrCtD
Lapatinib—EGFR—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—systemic scleroderma	0.000347	0.00257	CbGpPWpGaD
Lapatinib—Pruritus—Lisinopril—systemic scleroderma	0.000347	0.00137	CcSEcCtD
Lapatinib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000346	0.00136	CcSEcCtD
Lapatinib—EGFR—Thromboxane A2 receptor signaling—NOS3—systemic scleroderma	0.000343	0.00254	CbGpPWpGaD
Lapatinib—Rash—Mycophenolic acid—systemic scleroderma	0.000343	0.00135	CcSEcCtD
Lapatinib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000343	0.00135	CcSEcCtD
Lapatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000342	0.00253	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000341	0.00253	CbGpPWpGaD
Lapatinib—Headache—Mycophenolic acid—systemic scleroderma	0.000341	0.00134	CcSEcCtD
Lapatinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000339	0.00134	CcSEcCtD
Lapatinib—Nausea—Leflunomide—systemic scleroderma	0.000339	0.00134	CcSEcCtD
Lapatinib—Diarrhoea—Lisinopril—systemic scleroderma	0.000335	0.00132	CcSEcCtD
Lapatinib—EGFR—SHP2 signaling—NOS3—systemic scleroderma	0.000334	0.00247	CbGpPWpGaD
Lapatinib—ERBB2—Desoximetasone—Prednisone—systemic scleroderma	0.000332	0.0361	CbGdCrCtD
Lapatinib—Anaemia—Prednisone—systemic scleroderma	0.000329	0.0013	CcSEcCtD
Lapatinib—EGFR—LPA receptor mediated events—MMP2—systemic scleroderma	0.000329	0.00244	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—BLK—systemic scleroderma	0.000329	0.00244	CbGpPWpGaD
Lapatinib—PIK3C2B—Danazol—Prednisone—systemic scleroderma	0.000329	0.0357	CbGdCrCtD
Lapatinib—ABCB1—lung—systemic scleroderma	0.000324	0.00626	CbGeAlD
Lapatinib—Nausea—Mycophenolic acid—systemic scleroderma	0.000323	0.00127	CcSEcCtD
Lapatinib—EGFR—B Cell Activation—BLK—systemic scleroderma	0.000322	0.00239	CbGpPWpGaD
Lapatinib—EGFR—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000321	0.00238	CbGpPWpGaD
Lapatinib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000318	0.00125	CcSEcCtD
Lapatinib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000316	0.00125	CcSEcCtD
Lapatinib—Vomiting—Lisinopril—systemic scleroderma	0.000311	0.00123	CcSEcCtD
Lapatinib—Angiopathy—Methotrexate—systemic scleroderma	0.000311	0.00123	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—systemic scleroderma	0.000309	0.00122	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—CSK—systemic scleroderma	0.000309	0.00229	CbGpPWpGaD
Lapatinib—Rash—Lisinopril—systemic scleroderma	0.000309	0.00122	CcSEcCtD
Lapatinib—EGFR—Spinal Cord Injury—IL1A—systemic scleroderma	0.000309	0.00229	CbGpPWpGaD
Lapatinib—Dermatitis—Lisinopril—systemic scleroderma	0.000309	0.00122	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000308	0.00122	CcSEcCtD
Lapatinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000308	0.00122	CcSEcCtD
Lapatinib—Headache—Lisinopril—systemic scleroderma	0.000307	0.00121	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—CSK—systemic scleroderma	0.000304	0.00226	CbGpPWpGaD
Lapatinib—ERBB2—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000304	0.00225	CbGpPWpGaD
Lapatinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000304	0.0012	CcSEcCtD
Lapatinib—Arthralgia—Prednisone—systemic scleroderma	0.000304	0.0012	CcSEcCtD
Lapatinib—Myalgia—Prednisone—systemic scleroderma	0.000304	0.0012	CcSEcCtD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000303	0.00224	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—ITGAM—systemic scleroderma	0.000303	0.00224	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—CD247—systemic scleroderma	0.000303	0.00224	CbGpPWpGaD
Lapatinib—Alopecia—Methotrexate—systemic scleroderma	0.000302	0.00119	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000301	0.00119	CcSEcCtD
Lapatinib—EGFR—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000301	0.00223	CbGpPWpGaD
Lapatinib—Mental disorder—Methotrexate—systemic scleroderma	0.0003	0.00118	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—ITGAM—systemic scleroderma	0.000298	0.00221	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—CD247—systemic scleroderma	0.000298	0.00221	CbGpPWpGaD
Lapatinib—Malnutrition—Methotrexate—systemic scleroderma	0.000298	0.00118	CcSEcCtD
Lapatinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000294	0.00116	CcSEcCtD
Lapatinib—TAP1—Immune System—HLA-DQB1—systemic scleroderma	0.000293	0.00217	CbGpPWpGaD
Lapatinib—Nausea—Lisinopril—systemic scleroderma	0.000291	0.00115	CcSEcCtD
Lapatinib—Anaphylactic shock—Prednisone—systemic scleroderma	0.000291	0.00115	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—CD247—systemic scleroderma	0.000291	0.00215	CbGpPWpGaD
Lapatinib—Infection—Prednisone—systemic scleroderma	0.000289	0.00114	CcSEcCtD
Lapatinib—Back pain—Methotrexate—systemic scleroderma	0.000288	0.00114	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—CD247—systemic scleroderma	0.000286	0.00212	CbGpPWpGaD
Lapatinib—EGFR—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—systemic scleroderma	0.000286	0.00212	CbGpPWpGaD
Lapatinib—Nervous system disorder—Prednisone—systemic scleroderma	0.000285	0.00113	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—TNFAIP3—systemic scleroderma	0.000283	0.0021	CbGpPWpGaD
Lapatinib—Skin disorder—Prednisone—systemic scleroderma	0.000283	0.00112	CcSEcCtD
Lapatinib—PIK3C2B—Metabolism—CTGF—systemic scleroderma	0.000279	0.00207	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—TNFAIP3—systemic scleroderma	0.000279	0.00207	CbGpPWpGaD
Lapatinib—TAP1—Immune System—IL1A—systemic scleroderma	0.000278	0.00206	CbGpPWpGaD
Lapatinib—Anorexia—Prednisone—systemic scleroderma	0.000277	0.00109	CcSEcCtD
Lapatinib—TAP1—Immune System—CD40LG—systemic scleroderma	0.000276	0.00205	CbGpPWpGaD
Lapatinib—ERBB2—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	0.000276	0.00204	CbGpPWpGaD
Lapatinib—Anaemia—Methotrexate—systemic scleroderma	0.000275	0.00109	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000275	0.00203	CbGpPWpGaD
Lapatinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000273	0.00108	CcSEcCtD
Lapatinib—ERBB2—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000272	0.00202	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—RHOB—systemic scleroderma	0.000271	0.00201	CbGpPWpGaD
Lapatinib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000271	0.00107	CcSEcCtD
Lapatinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00027	0.00107	CcSEcCtD
Lapatinib—PI4KB—Metabolism—CTGF—systemic scleroderma	0.00027	0.002	CbGpPWpGaD
Lapatinib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000269	0.00106	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—BLK—systemic scleroderma	0.000269	0.00199	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000268	0.00199	CbGpPWpGaD
Lapatinib—Leukopenia—Methotrexate—systemic scleroderma	0.000267	0.00105	CcSEcCtD
Lapatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000266	0.00197	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000265	0.00105	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—BLK—systemic scleroderma	0.000265	0.00196	CbGpPWpGaD
Lapatinib—Insomnia—Prednisone—systemic scleroderma	0.000263	0.00104	CcSEcCtD
Lapatinib—Cough—Methotrexate—systemic scleroderma	0.00026	0.00103	CcSEcCtD
Lapatinib—Dyspepsia—Prednisone—systemic scleroderma	0.000256	0.00101	CcSEcCtD
Lapatinib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000255	0.00101	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—systemic scleroderma	0.000254	0.001	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—systemic scleroderma	0.000254	0.001	CcSEcCtD
Lapatinib—Decreased appetite—Prednisone—systemic scleroderma	0.000253	0.000998	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000252	0.000994	CcSEcCtD
Lapatinib—Fatigue—Prednisone—systemic scleroderma	0.000251	0.00099	CcSEcCtD
Lapatinib—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000249	0.00185	CbGpPWpGaD
Lapatinib—Constipation—Prednisone—systemic scleroderma	0.000249	0.000982	CcSEcCtD
Lapatinib—EGFR—LPA receptor mediated events—MMP9—systemic scleroderma	0.000248	0.00183	CbGpPWpGaD
Lapatinib—ERBB2—Disease—SMAD7—systemic scleroderma	0.000246	0.00182	CbGpPWpGaD
Lapatinib—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000243	0.000959	CcSEcCtD
Lapatinib—ERBB4—Disease—SMAD7—systemic scleroderma	0.000242	0.00179	CbGpPWpGaD
Lapatinib—EGFR—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000242	0.00179	CbGpPWpGaD
Lapatinib—Infection—Methotrexate—systemic scleroderma	0.000242	0.000953	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000238	0.000941	CcSEcCtD
Lapatinib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000238	0.000939	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—systemic scleroderma	0.000236	0.000932	CcSEcCtD
Lapatinib—EGFR—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000233	0.00172	CbGpPWpGaD
Lapatinib—Anorexia—Methotrexate—systemic scleroderma	0.000232	0.000915	CcSEcCtD
Lapatinib—Abdominal pain—Prednisone—systemic scleroderma	0.00023	0.000908	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000226	0.00168	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TGFBI—systemic scleroderma	0.000225	0.00166	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000222	0.000874	CcSEcCtD
Lapatinib—ERBB4—Disease—TGFBI—systemic scleroderma	0.000221	0.00164	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—CTLA4—systemic scleroderma	0.00022	0.00163	CbGpPWpGaD
Lapatinib—Insomnia—Methotrexate—systemic scleroderma	0.00022	0.000868	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—CTLA4—systemic scleroderma	0.000217	0.00161	CbGpPWpGaD
Lapatinib—Dyspnoea—Methotrexate—systemic scleroderma	0.000217	0.000855	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000215	0.00159	CbGpPWpGaD
Lapatinib—Hypersensitivity—Prednisone—systemic scleroderma	0.000214	0.000846	CcSEcCtD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000214	0.00159	CbGpPWpGaD
Lapatinib—Dyspepsia—Methotrexate—systemic scleroderma	0.000214	0.000845	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000214	0.00158	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—CCL2—systemic scleroderma	0.000212	0.00157	CbGpPWpGaD
Lapatinib—Decreased appetite—Methotrexate—systemic scleroderma	0.000211	0.000834	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00021	0.000828	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—systemic scleroderma	0.00021	0.000827	CcSEcCtD
Lapatinib—Asthenia—Prednisone—systemic scleroderma	0.000209	0.000824	CcSEcCtD
Lapatinib—Pruritus—Prednisone—systemic scleroderma	0.000206	0.000812	CcSEcCtD
Lapatinib—Diarrhoea—Prednisone—systemic scleroderma	0.000199	0.000786	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000199	0.000785	CcSEcCtD
Lapatinib—EGFR—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000194	0.00144	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—RHOB—systemic scleroderma	0.000193	0.00143	CbGpPWpGaD
Lapatinib—Abdominal pain—Methotrexate—systemic scleroderma	0.000192	0.000758	CcSEcCtD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000192	0.00142	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CSK—systemic scleroderma	0.000187	0.00139	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—MMP2—systemic scleroderma	0.000186	0.00138	CbGpPWpGaD
Lapatinib—Vomiting—Prednisone—systemic scleroderma	0.000185	0.00073	CcSEcCtD
Lapatinib—ERBB4—Immune System—CSK—systemic scleroderma	0.000185	0.00137	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IRF5—systemic scleroderma	0.000184	0.00137	CbGpPWpGaD
Lapatinib—Rash—Prednisone—systemic scleroderma	0.000183	0.000724	CcSEcCtD
Lapatinib—Dermatitis—Prednisone—systemic scleroderma	0.000183	0.000723	CcSEcCtD
Lapatinib—Headache—Prednisone—systemic scleroderma	0.000182	0.000719	CcSEcCtD
Lapatinib—ERBB4—Immune System—IRF5—systemic scleroderma	0.000182	0.00135	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000181	0.00134	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HSPG2—systemic scleroderma	0.000179	0.00133	CbGpPWpGaD
Lapatinib—Hypersensitivity—Methotrexate—systemic scleroderma	0.000179	0.000707	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000179	0.00132	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HSPG2—systemic scleroderma	0.000177	0.00131	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IRF8—systemic scleroderma	0.000176	0.00131	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD247—systemic scleroderma	0.000176	0.00131	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—ITGAM—systemic scleroderma	0.000176	0.00131	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—MMP2—systemic scleroderma	0.000176	0.00131	CbGpPWpGaD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000176	0.0013	CbGpPWpGaD
Lapatinib—Asthenia—Methotrexate—systemic scleroderma	0.000174	0.000688	CcSEcCtD
Lapatinib—ERBB4—Immune System—CD247—systemic scleroderma	0.000174	0.00129	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IRF8—systemic scleroderma	0.000174	0.00129	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—ITGAM—systemic scleroderma	0.000174	0.00129	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CSK—systemic scleroderma	0.000173	0.00128	CbGpPWpGaD
Lapatinib—Nausea—Prednisone—systemic scleroderma	0.000173	0.000682	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—systemic scleroderma	0.000172	0.000679	CcSEcCtD
Lapatinib—ERBB2—Signaling Pathways—SMAD7—systemic scleroderma	0.000172	0.00127	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—CD40LG—systemic scleroderma	0.000171	0.00127	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CSK—systemic scleroderma	0.00017	0.00126	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SMAD7—systemic scleroderma	0.000169	0.00126	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—CD40LG—systemic scleroderma	0.000169	0.00125	CbGpPWpGaD
Lapatinib—Diarrhoea—Methotrexate—systemic scleroderma	0.000166	0.000656	CcSEcCtD
Lapatinib—ERBB2—Immune System—TNFAIP3—systemic scleroderma	0.000165	0.00122	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—BLK—systemic scleroderma	0.000163	0.00121	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CD247—systemic scleroderma	0.000163	0.00121	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—TNFAIP3—systemic scleroderma	0.000163	0.0012	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—IL1B—systemic scleroderma	0.000161	0.00119	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—BLK—systemic scleroderma	0.000161	0.00119	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CD247—systemic scleroderma	0.00016	0.00119	CbGpPWpGaD
Lapatinib—Vomiting—Methotrexate—systemic scleroderma	0.000155	0.00061	CcSEcCtD
Lapatinib—Rash—Methotrexate—systemic scleroderma	0.000153	0.000605	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—systemic scleroderma	0.000153	0.000604	CcSEcCtD
Lapatinib—Headache—Methotrexate—systemic scleroderma	0.000152	0.000601	CcSEcCtD
Lapatinib—EGFR—Spinal Cord Injury—MMP9—systemic scleroderma	0.000152	0.00112	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CSK—systemic scleroderma	0.000149	0.00111	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000147	0.00109	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CD247—systemic scleroderma	0.000146	0.00108	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—ITGAM—systemic scleroderma	0.000146	0.00108	CbGpPWpGaD
Lapatinib—TAP1—Immune System—IL1B—systemic scleroderma	0.000145	0.00107	CbGpPWpGaD
Lapatinib—Nausea—Methotrexate—systemic scleroderma	0.000144	0.00057	CcSEcCtD
Lapatinib—EGFR—Adaptive Immune System—CD247—systemic scleroderma	0.00014	0.00104	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—MMP9—systemic scleroderma	0.00014	0.00104	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—TNFAIP3—systemic scleroderma	0.000137	0.00101	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CTLA4—systemic scleroderma	0.000134	0.00099	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—RHOB—systemic scleroderma	0.000133	0.000986	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—MMP2—systemic scleroderma	0.000133	0.000984	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000132	0.000975	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CTLA4—systemic scleroderma	0.000132	0.000975	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—RHOB—systemic scleroderma	0.000131	0.000971	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—BLK—systemic scleroderma	0.00013	0.000963	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HSPG2—systemic scleroderma	0.000125	0.00093	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000125	0.000927	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HSPG2—systemic scleroderma	0.000124	0.000916	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—NOS3—systemic scleroderma	0.000122	0.000901	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000121	0.000899	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CSK—systemic scleroderma	0.000121	0.000898	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CSK—systemic scleroderma	0.000119	0.000885	CbGpPWpGaD
Lapatinib—EGFR—Disease—SMAD7—systemic scleroderma	0.000119	0.00088	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism—NOS3—systemic scleroderma	0.000117	0.00087	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	0.000112	0.00083	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-DQB1—systemic scleroderma	0.00011	0.000815	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—RHOB—systemic scleroderma	0.000109	0.000807	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFBI—systemic scleroderma	0.000109	0.000805	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HLA-DQB1—systemic scleroderma	0.000108	0.000803	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CTLA4—systemic scleroderma	0.000106	0.000789	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL1A—systemic scleroderma	0.000104	0.000774	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD40LG—systemic scleroderma	0.000104	0.00077	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL1A—systemic scleroderma	0.000103	0.000762	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD40LG—systemic scleroderma	0.000102	0.000758	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—MMP9—systemic scleroderma	9.99e-05	0.00074	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	9.44e-05	0.000699	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TGFB1—systemic scleroderma	9.43e-05	0.000699	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CSK—systemic scleroderma	9.06e-05	0.000671	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MMP2—systemic scleroderma	9e-05	0.000667	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IRF5—systemic scleroderma	8.92e-05	0.000661	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	8.77e-05	0.00065	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	8.7e-05	0.000645	CbGpPWpGaD
Lapatinib—EGFR—Disease—HSPG2—systemic scleroderma	8.66e-05	0.000642	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IRF8—systemic scleroderma	8.52e-05	0.000631	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ITGAM—systemic scleroderma	8.52e-05	0.000631	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD247—systemic scleroderma	8.52e-05	0.000631	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	8.51e-05	0.000631	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.42e-05	0.000624	CbGpPWpGaD
Lapatinib—EGFR—Disease—CSK—systemic scleroderma	8.37e-05	0.00062	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SMAD7—systemic scleroderma	8.32e-05	0.000616	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD40LG—systemic scleroderma	8.28e-05	0.000613	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—TGFB1—systemic scleroderma	8.23e-05	0.00061	CbGpPWpGaD
Lapatinib—EGFR—Immune System—TNFAIP3—systemic scleroderma	7.98e-05	0.000591	CbGpPWpGaD
Lapatinib—EGFR—Immune System—BLK—systemic scleroderma	7.88e-05	0.000584	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD247—systemic scleroderma	7.87e-05	0.000583	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.15e-05	0.00053	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—EDN1—systemic scleroderma	6.79e-05	0.000503	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MMP9—systemic scleroderma	6.77e-05	0.000501	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—EDN1—systemic scleroderma	6.69e-05	0.000496	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CTLA4—systemic scleroderma	6.46e-05	0.000478	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—RHOB—systemic scleroderma	6.43e-05	0.000477	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MMP2—systemic scleroderma	6.42e-05	0.000476	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.38e-05	0.000473	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HSPG2—systemic scleroderma	6.07e-05	0.00045	CbGpPWpGaD
Lapatinib—ERBB2—Disease—NOS3—systemic scleroderma	5.91e-05	0.000438	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CSK—systemic scleroderma	5.86e-05	0.000434	CbGpPWpGaD
Lapatinib—ERBB4—Disease—NOS3—systemic scleroderma	5.82e-05	0.000431	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—EDN1—systemic scleroderma	5.56e-05	0.000412	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL1B—systemic scleroderma	5.45e-05	0.000404	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL1B—systemic scleroderma	5.37e-05	0.000398	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-DQB1—systemic scleroderma	5.32e-05	0.000394	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL1A—systemic scleroderma	5.05e-05	0.000374	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD40LG—systemic scleroderma	5.02e-05	0.000372	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	4.85e-05	0.00036	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MMP9—systemic scleroderma	4.83e-05	0.000358	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCL2—systemic scleroderma	4.64e-05	0.000344	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCL2—systemic scleroderma	4.57e-05	0.000339	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.3e-05	0.000318	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	4.2e-05	0.000311	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NOS3—systemic scleroderma	4.14e-05	0.000307	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NOS3—systemic scleroderma	4.08e-05	0.000302	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TGFB1—systemic scleroderma	3.98e-05	0.000295	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TGFB1—systemic scleroderma	3.91e-05	0.00029	CbGpPWpGaD
Lapatinib—ERBB4—Disease—TGFB1—systemic scleroderma	3.85e-05	0.000285	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCL2—systemic scleroderma	3.8e-05	0.000282	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	3.75e-05	0.000278	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	3.68e-05	0.000273	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	3.66e-05	0.000271	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MMP9—systemic scleroderma	3.32e-05	0.000246	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EDN1—systemic scleroderma	3.28e-05	0.000243	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MMP9—systemic scleroderma	3.27e-05	0.000242	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CTGF—systemic scleroderma	3.19e-05	0.000236	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOS3—systemic scleroderma	2.86e-05	0.000212	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CTGF—systemic scleroderma	2.84e-05	0.000211	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CTGF—systemic scleroderma	2.78e-05	0.000206	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TGFB1—systemic scleroderma	2.74e-05	0.000203	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TGFB1—systemic scleroderma	2.7e-05	0.0002	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL1B—systemic scleroderma	2.63e-05	0.000195	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.26e-05	0.000167	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL2—systemic scleroderma	2.25e-05	0.000166	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOS3—systemic scleroderma	2e-05	0.000148	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFB1—systemic scleroderma	1.89e-05	0.00014	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.71e-05	0.000127	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—systemic scleroderma	1.61e-05	0.000119	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.6e-05	0.000119	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NOS3—systemic scleroderma	1.39e-05	0.000103	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFB1—systemic scleroderma	1.32e-05	9.81e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NOS3—systemic scleroderma	1.24e-05	9.17e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NOS3—systemic scleroderma	1.21e-05	8.95e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	7.44e-06	5.51e-05	CbGpPWpGaD
